LAUSR

OBJECTIVE Survival of patients with monogenic Parkinson's disease may depend on the causative genes associated with the disease. In this study, we compare survival of patients with Parkinson's disease according to the presence of SNCA, PRKN, LRRK2 or GBA mutations. METHODS Data from the French Parkinson Disease Genetics national multicentre cohort study was used. Patients with sporadic and familial Parkinson's disease were recruited between 1990-2021. Patients were genotyped for the presence of mutations in the SNCA, PRKN, LRRK2 or GBA genes. Vital status was collected from the National death register for participants born in France. Hazard ratios (HR, 95% confidence intervals [CI]) were computed using multivariable Cox proportional hazards regression. RESULTS Of the 2,037 patients with Parkinson's disease, 889 had died after a follow-up of up to 30 years. Patients with PRKN (n=100, HR=0.41; P=.001) and LRRK2 mutations (n=51, HR=0.49; P=.023) had longer survival than those without any mutation, while patients with SNCA (n=20, HR=9.88; P<.001) or GBA mutations (n=173, HR=1.33; P=.048) had shorter survival. INTERPRETATION Survival differs across genetic forms of Parkinson's disease, with higher mortality for patients with SNCA or GBA mutations, and lower mortality for those with PRKN or LRRK2 mutations. Differences in severity and disease progression among monogenic forms of Parkinson's disease likely explain these findings, which has important consequences for genetic counselling and choice of endpoints for future clinical trials for targeted therapies. This article is protected by copyright. All rights reserved.